Altmetric

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial.




COUNTER-compliant statistics provided by IRUS-UK.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.